Merck KGaA's CEO reaffirmed the company's commitment to a disciplined mergers and acquisitions (M&A) strategy during the recent earnings call, emphasizing a continued focus on the life sciences unit. The CEO indicated that the company plans to pursue business development opportunities aggressively within a range of zero to $15 billion, despite uncertain market conditions. Discussions also touched on China-based acquisitions and innovation, highlighting the company's strategic interest in these areas. Meanwhile, developments in the biotech sector, including competition related to CRISPR technology, were noted, underscoring the dynamic environment in which Merck operates.